Latterell Venture Partners

https://www.lvpcapital.com

Last activity: 31.03.2015

Active

Mentions

Overview

Investment Type

Venture Capital

Mentions in press and media 16

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Dec 17, 2012	Naurex Raises $38M in Series B Financing	Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology, has raised $38m in Series B financing. The round was led by new investor Baxter Ventures, with participation from new investor Savitr Capit...
Dec 17, 2012	Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M	The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised $32 million in a Series C round. Among the company’s institutional investors are Clarus Ventures, HealthCare Ventures, Quaker Partners, Novi...
Nov 9, 2011	Inova Labs Secures $17.5M in Series B Funding	Inova Labs, an Austin, Texas-based medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) market, has secured an up to $17.5m Series B round of equity financing. The round was l...
Jun 11, 2009	Sans IPO, Bayhill secures $350M in Genentech licensing deal	Months after giving up on its IPO hopes last year — when the market was especially brutal for lifescience companies — Bayhill Therapeutics has landed a licensing deal worth $25 million in upfront cash and equity with Genentech. It could bri...
May 11, 2009	Revascular adds $3M to clear arteries	Revascular Therapeutics, maker of a device that helps doctors clear blockages in major arteries, has tacked on $3 million to a second round of funding, bringing its total to $11 million, reports VentureWire. The Sunnyvale, Calif., company h...
Apr 10, 2009	Cell Biosciences to launch new tech with $10M	Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that...
Mar 30, 2009	Pathway Medical lands generous $40M to treat arterial disease	Pathway Medical Technologies, maker of a non-invasive catheter capable of removing all kinds of artery blockages and build-up, says it just scored $40 million in a fourth round of funding — a pretty high figure for a life science device man...
Mar 26, 2009	Neuraltus scores $17M to treat degenerative brain disease	Neuraltus Pharmaceuticals, developer of drugs used to treat degenerative neurological diseases, brought in $17 million in a first round of funding from Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners. The...
Nov 4, 2008	OncoMed nabs $93M for stem cell programs	OncoMed Pharmaceuticals, a company working to fight cancer using stem cells, added a $93 million tranche to a second round of funding that now totals $154 million. The money will be used to push its lead antibody candidate through phase-two...
Sep 9, 2008	Proteolix raises $79M for cancer treatment	Proteolix, which is developing drugs to treat cancer by disrupting key cell functions, has raised $79 million in a third round of funding, according to VentureWire. That’s the third largest biotech funding this year. Nomura Phase4 Ventures,...
Jul 3, 2007	Stent maker CardioMind raises $33M	CardioMind, a secretive Sunnyvale, Calif., developer of stents designed to prop open blocked arteries, raised $33 million in a third round of funding, VentureWire reports (subscription required). From the VentureWire story: CardioMind, with...
May 29, 2007	Talima Therapeutics raises $19M for site-specific drugs	Talima Therapeutics, a Santa Clara, Calif., developer of techniques that limit drug delivery to specific parts of the body, raised $19 million in a second funding round. The company’s release is here. The company is at work on localized dru...
May 7, 2007	Lung-device maker Pulmonx draws in $20M	Palo Alto, Calif.-based Pulmonx raised $20 million in a second-round funding, VentureWire reports (subscription required). The startup is one of several device makers hoping to pioneer new medical techniques in the field of “interventional ...
	PerceptiMed raising $5M to commercialize medication validation tools to avoid patient error	The statistic that PerceptiMed CEO and co-founder Dr Alan Jacobs throws at me sounds terrible — one out of 30 pills is an incorrect drug or dosage or goes to the wrong person. It is part of the challenge to improve patient safety that’s pro...
	Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M	A company with a small molecule cancer treatment to combat solid tumor cancers as well as hematological malignancies has raised $5 million in a combination of debt, options and warrants, according to a Form D filing with the Securities and ...

Reviews 0

FAQ about Latterell Venture Partners

What has the press written about Latterell Venture Partners?

Parsers VC has collected 16 articles mentioning Latterell Venture Partners, among them “Naurex Raises $38M in Series B Financing” (Dec 17, 2012) and “Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M” (Dec 17, 2012).

Is Latterell Venture Partners still active?

Yes, Latterell Venture Partners is active; its latest activity on Parsers VC dates from Mar 31, 2015.